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In Europe, commercially available extracts from the white-berry mistletoe (Viscum album L.) are widely used as a complementary
cancer therapy. Mistletoe lectins have been identiﬁed as main active components and exhibit cytotoxic eﬀects as well as
immunomodulatory activity. Since it is still not elucidated in detail how mistle toe extracts such as ISCADOR communicate their
eﬀects, we analyzed the mechanisms that might be responsible for their antitumoral function on a molecular and functional level.
ISCADOR-treated glioblastoma (GBM) cells down-regulate central genes involved in glioblastoma progression and malignancy
such as the cytokine TGF-β and matrix-metalloproteinases. Using in vitro glioblastoma/immune cell co-cultivation assays as well
as measurement of cell migration and invasion, we could demonstrate that in glioblastoma cells, lectin-rich ISCADOR M and
ISCADOR Q signiﬁcantly enforce NK-cell-mediated GBM cell lysis. Beside its immune stimulatory eﬀect, ISCADOR reduces the
migratory and invasive potential of glioblastoma cells. In a syngeneic as well as in a xenograft glioblastoma mouse model, both
pretreatment of tumor cells and intratumoral therapy of subcutaneously growing glioblastoma cells with ISCADOR Q showed
delayed tumor growth. In conclusion, ISCADOR Q, showing multiple positive eﬀects in the treatment of glioblastoma, may be a
candidate for concomitant treatment of this cancer.
1.Introduction
Glioblastoma (GBM) is the most common malignant brain
tumor with an incidence of 3.5 cases per 100.000 people
per year. GBM are among the most lethal neoplasms with
a median survival of approximately one year after diagnosis
even upon maximum current treatment strategies. Only
few therapeutic regimens such as the chemotherapeutic
drug temozolomide (TMZ) provide a short but signiﬁ-
cant increase in survival [1]. Additionally, tumor-intrinsic
features including the methylation status of the O-(6)-
methylguanine-DNA methyltransferase (MGMT) promoter
are also predictive for the survival of GBM patients [2]. The
failure of eﬀective therapy regimens in malignant GBM is
associated with its malignant characteristics which means
thatthesetumorsarehighlyresistanttocelldeath[3],possess
immunosuppressive function [4] and show a highly invasive
and destructive growth due to their migratory and invasive
growth potential [5].
Extracts of the European mistletoe (Viscum album L.)
have been widely used for decades as alternative, comple-
mentary treatment and adjuvant cancer therapy, especially
in German-speaking countries. Cytotoxic glycoproteins,
the mistletoe lectins (ML), are one active component of
mistletoe extracts and can stimulate eﬀector cells of the
innate and adaptive immune system such as dendritic cells,
macrophages, natural killer cells, and B and T lymphocytes,
at least one mechanism that might be responsible for the2 Evidence-Based Complementary and Alternative Medicine
antitumoral properties of mistletoe extracts (ME) [6–13].
Beside their immune modulatory function, ME show direct
growth inhibition and cell death induction in tumor cells
such as induction of apoptosis or direct necrotic eﬀects,
dependent on the concentration used for treatment [14–21].
In vivo, preclinical activity of aqueous ME has been shown in
a variety of transplantable rodent tumor models [22–26]. In
clinical cancer therapy studies, adjuvant treatment with ME
showed an impact on the patients’ quality of life, reducing
side eﬀects of conventional therapies such as nausea, fatigue
or reduced energy induced by chemotherapy or radiation,
and is associated with prolonged survival [27–31], even in
glioma [32].
One of the longest known mistletoe preparations is the
fermented plant extract ISCADOR which is extracted from
mistletoe plants growing on diﬀerent host trees like apple
(ISCADOR M), oak (ISCADOR Q), or pine (ISCADOR P).
ISCADOR P contains only very small amounts of lectin,
whilst lectin content in ISCADOR Q is high and medium
in ISCADOR M. Especially natural killer (NK) cells as part
of the innate immune system play an essential role in cell-
mediated immune responses against tumor cells, also in
glioma [33], and it has been shown before that ISCADOR
treatment had a positive eﬀect on NK cell function [9,
34]. There are ﬁrst hints that the ISCADOR variants show
positive eﬀects using them as treatment agents for GBM,
but the mechanisms responsible for these eﬀects are not
well elucidated until today [26, 32], In the present study,
we especially aim to investigate the eﬀects of lectin rich
ISCADOR Q on GBM cell proliferation, cell death, cell
motility and immune-cell mediated anti-GBM immune
response to assess its antitumoral potential in gliomas.
2.MaterialandMethods
2.1. Cell Lines and Reagents. LNT-229 and LN-308 cell lines
were provided by N. de Tribolet (Lausanne, Switzerland).
These cells were chosen since both cell lines are well charac-
terised, and diﬀer in their growth capacity and genetic back-
ground [35]. Furthermore, LN-308 cells diﬀer from LNT-
229 cells in a reduced expression of the migration/invasion-
relevant matrix metalloproteinases MMP-2 and -9 [36, 37].
LNT-229-Luc cells used for immune cell lysis assays were
generated by stable transfection of the cells with pGL4.14-
HSV-Luc expressing ﬁreﬂy luciferase. SMA560 cells were a
friendly gift of G. J. Pilkington (Portsmouth, UK) [38, 39].
All cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM; GIBCO Life Technologies, Eggenstein,
Germany) containing 10% fetal calf serum (FCS), penicillin
(100 U/mL), streptomycin (100μg/mL), and the appropriate
antibiotics in a humidiﬁed atmosphere containing 5% CO2.
Unless otherwise noted, other reagents were from Sigma
(Munich, Germany).
2.2. Mistletoe Extracts. ISCADOR preparations were a
friendlygiftofWeleda,“Vereinf¨ urKrebsforschung,”Institute
Hiscia (Arlesheim, Switzerland). Charge numbers of diﬀer-
ent ISCADOR preparations were as follow: ISCADOR Q200:
1009/0325; ISCADOR P200: 0809/811, ISCADOR M20: 0711.
As communicated by the manufacturer, total ML content in
ISCADOR preparations were: 35ng/mL (P), 899ng/mL (M),
and 15050ng/mL (Q). Viscotoxin contents in the diﬀerent
ISCADOR preparations were: 160μg/mL (P), 36μg/mL (M)
and 364μg/mL (Q).
2.3. RNA Preparation and Quantitative RT-PCR. Total
RNA was prepared using the RNA Isolation Kit (Roche,
Mannheim, Germany) and was reverse transcribed using
Superscript II (Invitrogen, Karlsruhe, Germany). Target gene
expression was determined using SYBR green master mix
(Thermo Fisher Scientiﬁc, MA, USA), on an ABI 7500
system. Relative mRNA expression was quantiﬁed ([EΔCT
(speciﬁc primer)/EΔCT (GAPDH)]). The following primers
were used: GAPDH-frwd TGCACCACCAACTGCTTAGC,
GAPDH-rev GGCATGGACTGTGGTCATGAG; Ang1-frwd
CGGTGAATATTGGCTGGGG; Ang1-rev GTCATACTG-
TGAATAGGCTCGGTT, VEGFR2-frwd GTCCTAGAGCGT-
GTGGCACC, VEGFR2-rev CATGATCTGTGGAGGGGG-
ATTC. GAPDH primers were used for normalization.
2.4. PCR-Based Microarray Expression Analysis. Total RNA
and cDNA were obtained as described. For expression anal-
ysis of 96 genes involved in tumor cell motility and angio-
genesis,HumanAngiogenesis96-wellStellARrayqPCRarray
(Lonza,Basel,Switzerland)waspreparedaccordingtomanu-
facturer’sinstructionusing SYBRgreenmastermix (Thermo
Fisher Scientiﬁc, MA, USA) on an ABI 7500 system. Data
wereanalyzedwithGlobalPatternRecognitionDataAnalysis
Tool (Bar Harbor Biotechnology, Trenton, ME, USA) using
the internal array control housekeeping gene expression for
normalization.
2.5. Rembrandt Platform Analyses. The REMBRANDT
database contains microarray data for probes from the
Aﬀymetrix U133 Plus 2.0 GeneChip (National Cancer
Institute 2005; REMBRANDT home page: http://rembran-
dt.nci.nih.gov/ (accessed February 6, 2012)). At the time of
accession, the database contained mRNA expression data of
228 glioblastomas and 28 normal controltissues. P values for
median expression intensity changes between each glioma
subgroup compared to normal CNS tissue controls were
obtained.
2.6. ELISA. Cellular supernatants were collected from vehi-
cle or ISCADOR treated LNT-229 cells (ISCADOR Q;
100μg/mL) after incubation with serum-free medium. All
ELISA kits were used following the manufacturer’s protocol
(TGF-β1-ELISA: eBioscience, Frankfurt, Germany; TGF-β2-
ELISA: R&D Systems, Wiesbaden, Germany; Angiopoietin-
1-ELISA:R&DSystems,Wiesbaden,Germany,VEGF-ELISA:
Peprotech, Hamburg, Germany). Colorimetric quantiﬁca-
tion was performed on the ELISA-reader Multiskan Ex
(Thermo Fischer Scientiﬁc, MA, USA) at 450nm.
2.7. Growth and Viability Assays. Net cell culture growth and
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as described [40]. Cell viability was determined by Trypan
blue exclusion assay.
2.8. Analysis of Cell Death. For the caspase 3/7 activity assay
cells were seeded in microtiter plates, allowed to attach, and
treated with ISCADOR (100μg/mL). 24h later, the cells were
lysed in 25mM Tris-HCl (pH 8.0), 60mM NaCl, 2.5mM
EDTA, and 0.25% NP40 for 10min, and acetyl-DEVD-amc
was added at 12.5mM. Caspase activity was assessed by
ﬂuorescence using a Mithras LB940 ﬂuorimeter (Berthold
Technologies, Bad Wildbad, Germany) at 360nm excitation
and480nmemissionwavelengths.Toanalyzetotalcelldeath,
cells were trypsinized and stained with propidium iodide
(PI). The content of PI-positive cells was determined by
ﬂuorescence activated cell sorting (FACS) analysis.
2.9. Immunoblot Analysis. The general procedure has been
described [40]. Cellular supernatants were generated using
serum-depleted cell culture medium and concentrated using
Amicon concentrator columns (Millipore, Schwalbach, Ger-
many). The following antibodies were used: anti-MMP-2
(Millipore, Schwalbach, Germany), anti-MMP-9 (R&D Sys-
tems, Wiesbaden, Germany), anti-GAPDH (Chemicon,
Billerica, MA, USA), anti-MMP-1, and anti-MMP-3 (both
from Biolegend, Fell, Germany), anti-MMP-10 (R&D Sys-
tems, Wiesbaden, Germany), anti-MMP-14 (Epitomics,
Burlingame, CA, USA), and anti-TIMP-2 (R&D Systems,
Wiesbaden, Germany). Protein contents were quantiﬁed
usingtheAlpha-Innotec-LumiImager-Fluorchem-8900(Cell
Bioscience, Santa Clara, CA, USA).
2.10. Zymography. Cellular supernatants were collected,
concentrated, and 20μgp r o t e i nw a sl o a d e do nz y m o g r a m
gels (Bio-Rad Laboratories GmbH, M¨ unchen, Germany).
MMP activity was analyzed according to the manufacturer’s
protocol. Quantiﬁcation was done using the Alpha-Erase-
Software (Cell Bioscience, Santa Clara, CA, USA).
2.11. Measurement of Cell Migration and Invasion. The
Scratch assay and the Boyden chamber migration assay
havepreviouslybeendescribed[41].Matrigel-coatedBoyden
chambers (BD Biosciences, Heidelberg, Germany) were used
for invasion assays.
2.12. FACS-Based Analysis. For expression analysis of
NKG2D ligands, growing cells were detached from cell cul-
ture ﬂasks using accutase (PAA, C¨ olbe, Germany). The cells
were prepared according to the manufacturers instruction
and surface protein expression was analyzed using puriﬁed
ascites supernatants against MICA (clone AMO1), MICB
(clone BMO1), ULBP1 (clone AUMO1), ULBP2 (clone
BUMO1), or MHC I (clone W6.32) (kindly provided
Alexander Steinle, Institute for Molecular Medicine, Frank-
furt Main, Germany; [42]). For DNAX accessory molecule
(DNAM)-1 ligands, anti-CD112-APC and anti CD155-PE
(both from Ebioscience, Frankfurt, Germany) were used.
Subsequently, the following secondary antibodies were used:
Cy3-conjugatedmouseIgG1(Dianova,Hamburg,Germany)
or APC-conjugated mouse IgG1 or IgG2 (Immunotools,
Friesoythe, Germany). The cells were subjected to ﬂow
cytometric analysis using a Cyan-ADP cytometer (DAKO
GmbH, Hamburg, Germany).
2.13. Puriﬁcation of PBL, Isolation, and Activation of Immune
Eﬀector Cells. Peripheral blood mononuclear cells (PBMC)
were isolated from EDTA-anticoagulated peripheral venous
blood of healthy donors by density gradient centrifugation
(Biocoll, Biochrom KG, Berlin, Germany). Monocytes were
removed from the PBMCs by allowing them to adhere to
tissue culture plastic. The nonadherent fraction (PBLs) was
then cocultured with irradiated RPMI 8866 feeder cells to
obtain polyclonal NK cell populations [22]. CD3+ T cells
were isolated from freshly isolated PBMCs using the Pan
T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany).CD3+Tcellswerethenstimulatedwith30ng/mL
of anti-CD3 antibody (clone OKT-3; eBioscience, Frank-
furt, Germany) irradiated feeder cells and 50U/mL human
recombinant IL-2 (Immunotools, Friesoythe, Germany) as
previously described [43]. On day 12 of the expansion cycle
the activation status based on expression of CD25 (antihu-
man CD25-PE conjugated anitbody, Miltenyi Biotec) and
HLA-DR (antihuman HLA-DR-FITC conjugated antibody,
eBioscience) was examined by FACS analysis. These cells
were used as eﬀectors in the lysis assays at day 14 of their
cycle.
2.14. Cellular Cytotoxicity Assay. Immune cell cytotoxicity
against human GBM cells was analyzed using a nonradioac-
tive assay measuring luciferase activity of stably transfected
LNT-229-Luc cells. Brieﬂy, target LNT-229-Luc cells were
incubated with ISCADOR or control medium for 24h. The
cells were washed and human PBLs, isolated NK cells or
activated CD3+ T cells of healthy donors were added to
the target cells and incubated for 4h at 37◦C. Viable cells
were determined by measuring luciferase activity using a
Mithras LB940 ﬂuorimeter (Berthold Technologies, Bad
Wildbad, Germany). The experimental lysis was corrected
by division by the spontaneous lysis of target cells at the
corresponding ISCADOR concentration or control-treated
cells. Percentage of lysis was calculated as followed: 100 −
((experimental lysis/spontaneous lysis) × 100). Experiments
were done in triplets. For inactivation of NK cells, the
cultures were preincubated with anti-NKG2D-antibodies
(R&D Systems, Wiesbaden, Germany) for 0.5h prior to
coculture with GBM cells according to the manufacturer’s
instruction.
ForanalysisofNKcellattachment,puriﬁedNKcellswere
loaded with CSFE (10μM) for 10min and then cultivated
on glioma cells for 1h. Cocultivated cells were washed
intensively with PBS to remove unattached NK cells and
microscopically documented using a Zeiss Axiovert 200M
ﬂuorescence microscope.
2.15. Mouse Experiments. Athymic CD1-deﬁcient NMRI
nude mice were purchased from Janvier (St. Berthevin,
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Tcells.VMDkmice[38,39]werebredinhouse.Miceof6–12
weeks of age were used in all experiments. The experiments
were performed according to the German law, Guide for
the Care and Use of Laboratory Animals (approval N3/09).
LNT-229 or SMA560 cells were treated with ISCADOR Q
(100μg/mL) or left untreated. The cells were trypsinized,
counted and viability was assessed by trypan-blue staining.
Groups of 6 mice were injected s.c. with one million viable
cells into the right ﬂank. Mice were examined regularly for
tumor growth using a metric caliper and sacriﬁced when
tumors reached 200mm2. To avoid artifacts due to cyto-
toxicity or proliferation inhibition induced by ISCADOR,
cell proliferation used for inoculation was analyzed. In brief,
1.000 cells were seeded in microtiter plates and allowed to
attach. Cell density was monitored every 24h by crystal
violet staining. For treatment of tumors with ISCADOR,
one million cells were implanted subcutaneously. Seven days
later, 2μg( 2 0 μL of a 100μg/mL stock) ISCADOR Q or
vehicle (PBS) was injected intratumorally. In a further exper-
iment, NMRI mice harboring subcutaneous tumors were
periodicallyandsubcutaneouslyinjectedonthecontralateral
body site with either PBS or with increasing concentrations
(1μgupto100μgineach100μL)ofISCADORQ.Micewere
examined regularly for tumor growth using a metric caliper,
and killed when tumors reached 200mm2.
2.16. Statistical Analysis. Figures show data obtained in at
least three up to ten independent experiments as indicated.
Quantitative data were assessed for signiﬁcant diﬀerences
using t-test ( ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.0001).
Statistical analysis of tumor growth in the animal experi-
ments was done using the ANOVA test (SPSS18, SPSS Inc,
Chicago, IL, USA). The results of the PCR-based microarray
expression analysis were analyzed together with the results
obtained for the corresponding genes in the REMBRANDT
database by a contingency table analysis. Nominal scaled
response variable (genes up- (1), non- (0), or down- (−1)
regulated in glioblastomas versus normal brain tissue in the
REMBRANDT database) and nominal explanatory variable
(same gene up- or downregulated in PCR-based microarray
expressionanalysisafterISCADORtreatment)wereanalysed
and subsequently tested in a likelihood ratio test. A signiﬁ-
cance level of alpha = 0.05 was chosen for all tests. Statistical
analysis to assess the association of the REMBRANDT and
our PCR-based microarray was performed using JMP 8.0
software (SAS, Cary, NC, USA).
3. Results
3.1. ISCADOR Signiﬁcantly Reduces the Expression of Genes
Associated with Malignancy and Progression in Glioblastomas.
To assess whether ISCADOR treatment might modulate
gene expression in glioma cells, we ﬁrst performed a PCR-
based microarray expression analysis. This array contains
a variety of genes involved in glioma-associated pathways
such as proliferation, survival, migration, invasion, and
angiogenesis as well as tumor-immunological processes.
As shown in Figure 1(a), treatment of glioma cells with
ISCADOR Q reduced the expression of a variety of genes
relevant for gliomagenesis: epidermal growth factor receptor
2(EGFR2/HER2/ERBB2)stimulatesproliferationandblocks
apoptosis [44], whereas BIRC5/Survivin is a potent inhibitor
of apoptosis [45]. PKB/AKT1 protein kinase plays a key role
in multiple cellular processes such as glucose metabolism,
cell proliferation, apoptosis, transcription, and cell migra-
tion [46, 47]. Constitutive signal transducer and activator
of transcription 3 (STAT3) activation is associated with
various human cancers, commonly suggests poor prognosis
and provides antiapoptotic as well as proliferative eﬀects
[48]. Genes such as matrix-metalloproteinases (MMP), cell
adhesion molecules such as platelet/endothelial cell adhesion
molecule (PECAM)-1, or integrins are important players
in cell motility whereas vascular endothelial growth factor
(VEGF), VEGF receptor type II (VEGFR2), and angiopoietin
(ANGPT)-1 and -related molecules as well as transforming
growth factor (TGF)-β are genes involved in both cell
motility and angiogenesis. The latter does not only enhance
tumor cell motility and angiogenesis, but also is the central
immunosuppressive molecule in GBM [5].
To verify reliability of microarray data, we exemplarily
analyzed expression of diﬀerentially regulated genes by
qPCR or ELISA. As shown in Figures 1(b)–1(e), there is a
signiﬁcant downregulation of TGF-β, ANGPT-1, VEGF, and
VEGFR2 upon ISCADOR treatment. Reduced gene expres-
sion is not a result of enhanced cell death, since ISCADOR
treatment conditions used for this analysis did not induce
cell death (Figure 3). We further analyzed the data obtained
fromthemicroarraysetforapotentialassociationwithgenes
regulated in glioblastomas versus normal CNS tissue in the
REMBRANDT database (Figure 1(f)). ISCADOR treatment
of LNT-229 glioma cells led to a relative increase of genes
which are signiﬁcantly higher in nonneoplastic CNS tissue
specimens in the REMBRANDT database while the percent-
age of genes signiﬁcantly upregulated in glioblastomas in the
REMBRANDT cohort decreased (P = 0.0047).
3.2. ISCADOR Treatment Reduces Glioma Cell Growth in
a Dose Dependent Manner. Since it has been shown that
mistletoe extracts could induce cell death and hold antipro-
liferative activity in a variety of tumor cell lines derived from
breast, lung, prostate, or renal cancer [14–19] and since we
have shown that in GBM cells ISCADOR downregulated
a variety of proliferation stimulating genes (Figure 1), we
analyzed whether ISCADOR was able to reduce cell growth
in human and mouse GBM cell lines, too. As shown in
Figure 2, lectin rich ISCADOR M and Q reduced cell growth
at doses of higher than 100μg/mL both in human LNT-
229 and in mouse SMA560 GBM cells, whereas ISCADOR
P showed only weak eﬀects on glioma cell growth. The cell
death inducing eﬀects of ISCADOR are dependent on their
content of viscotoxins and mistletoe lectins [14, 15]. The
cytotoxicandgrowthinhibitoryeﬀectsseenforISCADORM
and Q, but not for ISCADOR P in the GBM cell lines seemed
therefore to be only a minor eﬀect of viscotoxins present in
these ME, since all variants of ISCADOR used so far contain
viscotoxin,andeveniftheﬁnalconcentrationofviscotoxinisEvidence-Based Complementary and Alternative Medicine 5
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Figure 1:InGBMcells,ISCADORQchangestheexpressionofcancerassociatedgenes.(a)PCR-basedmicroarrayexpressionanalysis.LNT-
229 cells were treated with ISCADOR Q (100μg/mL) or were left untreated. 24h later, the cells were harvested, mRNA was prepared, reverse
transcribedintocDNAandusedformicroarray-basedexpressionanalysisonapanelof96migration-/invasion-angiogenesis-involvedgenes.
The best downregulated genes with a threshold > 3 are shown. (b) RT-PCR-based validation of diﬀerentially regulated genes detected in (a)
at 12 or 24h of ISCADOR Q treatment (n = 4, SEM). (c) TGF-β ELISA of ISCADOR Q treated LNT-229 cells. The cells were treated with
ISCADORQ(100μg/mL,24h)followedbyincubationinserum-freemediumfor48h.SupernatantswereharvestedandTGF-β1orT GF-β2
was quantiﬁed using ELISA (n = 4, SEM). (d) The cells were treated with ISCADOR Q (100μg/mL, 12 or 24h). Supernatants were harvested
48h later. Angiopoietin-1 content was analyzed using ELISA (n = 4, SEM). (e) The cells were treated as in (c). Supernatants were harvested
and VEGF content was analyzed using ELISA (n = 4, SEM). (f) Contingency table analysis of the PCR-based microarray expression data
together with the corresponding genes of the REMBRANDT database. Nominal scaled response variable (genes signiﬁcantly up- (1), non-
(0), or down- (−1) regulated in glioblastomas versus normal brain tissue expression pattern in the REMBRANDT database) and nominal
explanatory variable (same gene up- or downregulated in our PCR-based microarray expression analysis after ISCADOR treatment) were
analysed and subsequently tested by the likelihood ratio test (P = 0.0046).
comparable when treating the cells with diﬀerent ISCADOR
variants, high concentrations of ISCADOR P presenting a
higher amount of viscotoxin only marginally induced cell
death. The main diﬀerence between the ISCADOR variants
is their lectin concentration suggesting that ML are mainly
responsive for the cytotoxic eﬀects.
To analyze other eﬀects of ISCADOR in the treatment
of glioma cells beside the eﬀects on cell growth, for further
experiments an ISCADOR concentration of 100μg/mL was
chosen to avoid unwanted side eﬀects induced by inhibition
of proliferation or induction of cell death. The viscotoxin
contents at the ISCADOR concentration of 100μg/mL
which we have used for further studies were 80ng/mL (P),
180ng/mL(M),and182ng/mL(Q),totalMLconcentrations
were 0,017ng/mL (P), 4,49ng/mL (M), and 7,52ng/mL
(Q). At this concentration, no signiﬁcant reduction in cell
growth (Figure 3(a)) or induction of cell death (Figure 3(b))
or caspase activity (Figure 3(c)) were detectable. Even at
higherconcentrationsofISCADORQnocaspase3/7activity
was detectable, but cells became propidium iodide positive,
suggesting that the cells died by necrosis (data not shown).
3.3. ISCADOR Enhances PBL-Mediated GBM Cell Lysis.
Since we knew from the literature that ML can stimulate
immune eﬀector cells and since we have seen that the
secretion of TGF-β, the most important immunosuppressive6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: ISCADOR reduces glioma cell growth in a dose dependent manner. LNT-229 (a) or SMA560 cells (b) were treated of 24 or 48h
with increasing concentrations of ISCADOR or were left untreated. Cell density was assessed by crystal violet staining (n = 3, SEM).
cytokine in glioma, is decreased after treating the cells with
ISCADOR Q (Figure 1), we asked whether ISCADOR might
induce immune cell mediated GBM cell attack, too. Indeed,
ISCADOR treatment of LNT-229 cells, enhanced PBL-
mediated tumor cell lysis, dependent on the lectin content
of diﬀerent ISCADOR variants (Q > M > P; Figure 4(a)
and data not shown). ISCADOR mediated GBM-cell lysis is
dependent on the activity of NK cells, since preincubation of
PBLs with an inactivating NKG2D antibody neutralized the
lytic eﬀect (Figure 4(b)), whereas coincubation of ISCADOR
treated LNT-229 cells with puriﬁed NK cells also showed
enhanced cell lysis (Figure 4(c)). NK cell mediated tumor
cell lysis is dependent on the expression of so called
danger/stranger signaling molecules on target cells such as
the NKG2D ligands major histocompatibility complex I class
related (MIC)-A, MIC-B, or UL16 binding proteins (ULBP)
1, 2, 3, or the DNAX accessory molecule-(DNAM)-1 ligands
CD112 and CD115. To identify whether upregulation of
thesemoleculeswasinvolved intheenhancingPBLmediated
lytic eﬀect of ISCADOR treated GBM cells, we performed
FACS analysis to quantify surface protein expression. Neither
NKG2D- nor DNAM-1-ligand expression was altered after
treating the tumor cells with ISCADOR Q (data not shown).
We therefore analyzed whether enhanced NK cell mediated
glioma cell lysis might be an eﬀect of increased attachment
of NK cells to the target cells due to ML presented on the
target cell surface. For this, we cocultivated CSFE labeled NK
cells with ISCADOR Q pretreated glioma cells. As shown
in Figures 4(d) and 4(e), more NK cells were attached to
glioma cells if the target cells were pretreated with lectin rich
ISCADORQ,butnotifthecellsweretreatedwithlectinpoor
ISCADOR P, suggesting the ML boost NK cell attachment to
the GBM target cells.
In contrast to ISCADOR mediated enhancement of NK
cell activity, cocultivation of LNT-229 glioma cells with
puriﬁed and activated T cells did not show any diﬀerence in
the lysis of untreated compared to ISCADOR treated glioma
cells, also no changes in the cell surface expression of MHC
moleculesweredetectableonLNT-229cellsifthesecellswere
treated with ISCADOR (data not shown).
3.4. ISCADOR Reduces GBM Cell Motility. To analyze
whethertheISCADOR-mediatedreductionintheexpression
of migration/invasion-relevant genes cells resulted in a
reduction of glioma cell migration and invasion, we perfor-
med in vitro long lasting scratch assays, short time trans-
well boyden chamber migration as well as matrigel-invasion
assays. As shown in Figure 5, treatment of human (LNT-
229) and mouse (SMA-560) GBM cells with ISCADOR
reduced cell migration (Figures 5(a) and 5(b)) and inva-
sion (Figure 5(c)), revealing ISCADOR Q as the most
potent antimigratory ISCADOR variant. Interestingly, in
a second GBM cell line (LN-308) the antimigratory eﬀect of
ISCADOR Q was delayed compared to LNT-229 cells. LN-
308 cells diﬀer from LNT-229 cells in a reduced expression of
migration-/invasion-relevant MMPs 2 and −9( [ 36, 37]a n d
data not shown), indicating that altered MMP expression or
activity in ISCADOR-treated LNT-229 cells might be
responsible for the reduction of migration and invasion.
For this, we analyzed the expression and activity of
a variety of MMPs known to be expressed in GBM in control
and ISCADOR treated LNT-229 cells. As shown in
Figures 6(a) and 6(b), ISCADOR Q reduced the amount of
MMP-2 in cellular supernatants as well as the activity of all
MMP-2 subforms (72kD pro-MMP-2, 68kD active MMP-2
and the putative 36kD legumain-cleaved active MMP-2 vari-
ant[49];Figures 6(c) and 6(d)),whereasnochangeofMMP-
1, -3, and -10 protein expression was detectable. Even if
we have demonstrated reduced MMP-9 mRNA expression
upon ISCADOR treatment (Figure 1(a)), there was an in-
creased secretion of MMP-9 in ISCADOR Q treated cells.
However, MMP-9 activity was also impaired by ISCADOR
Q treatment (Figures 6(c) and 6(d)). Since it has been
described that the net MMP-2 activity correlates withEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Treatment of GBM cells with ISCADOR enhances NK cell mediated tumor cell lysis. (a) LNT-229-Luc cells were treated with
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the level of TIMP-2 expression [50], and knowing that under
certain conditions TIMP-2 can activate MMP-2 [51], we
analyzed TIMP-2 protein expression, demonstrating that
TIMP-2 is also downregulated in ISCADOR treated GBM
cells (Figure 6(a)).
3.5. ISCADOR Q Reduces Tumor Growth in Murine Glioma
Models. To analyze the eﬀects of ISCADOR Q on tumor
growth in vivo,w eu s e dt w od i ﬀerent mouse models. We
have chosen a xenograft model in which human LNT-229
GBM cells were subcutaneously implanted into the right
ﬂank of nude mice. For therapeutic intratumoral ISCADOR
treatment, mouse SMA560 glioma cells, representing a
spontaneously developed, poorly diﬀerentiated astrocytoma
in a VMDk mouse, were implanted in immunocompetent
VMDk mice [39]. As shown in Figures 7(a) and 7(b),b o t hEvidence-Based Complementary and Alternative Medicine 9
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Figure 5: ISCADOR reduces cell motility and invasiveness in human and mouse GBM cell lines. (a) Boyden chamber migration assays. The
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in the xenograft and in the syngeneic mouse model, pretreat-
ment of the implanted cells with ISCADOR Q (100μg/mL)
mitigated tumor growth indicating that the ISCADOR Q
antitumor eﬀects were also transferable to in vivo growing
tumors. To exclude that the diﬀerences in tumor growth
in ISCADOR Q and control treated tumors were a result
of altered cell proliferation or induction of cell death, we
analyzed cell growth in parallel. There were no diﬀerences
in proliferation in ISCADOR Q treated LNT-229 cells com-
pared to vehicle treated cells. For SMA560 cells, ISCADOR
Q delayed cell growth (insert in Figure 7(b)), but at 96h
after treatment, ISCADOR-treated cells reached the same10 Evidence-Based Complementary and Alternative Medicine
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Figure 6: ISCADOR Q mediated reduction of cell motility is caused by reduced MMP-expression and activity. (a) LNT-229 cells were
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(c) Gelatinase zymogram analyzing MMP activity (n = 10, one representative experiment is shown). (d) Quantiﬁcation of MMP gelatinase
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growth level than control cells suggesting that the diﬀerences
in tumor growth were not due to altered proliferation or
cell death. In a ﬁrst therapy model mimicking conditions
GBM patients use for ISCADOR treatment, the mice were
treated with repeated subcutaneous injections of ISCADOR
Q at increasing concentrations on the contralateral body site.
This model will give information if ISCADOR Q is able
to induce antitumoral activity by systemic application. As
shown in Figure 7(c), there was a slight, but not signiﬁcant
reduction of tumor growth in ISCADOR Q treated mice. In
a second therapy model we treated subcutaneously preim-
planted tumors with a single intratumoral injection (20μL,
100μg/mL) of ISCADOR Q. This amount of ISCADOR was
chosen since we wanted to gain information if an intra-
tumoral application of ISCADOR might exhibit antitumor
activity independent of its capacity to induce cell death or to
inhibit proliferation (Figures 2(b) and 3(b)). Tumor growth
was signiﬁcantly reduced when ISCADOR Q was directly
injected into the growing tumor mass. This suggests that
ISCADOR Q might unfurl its antitumor eﬀect best when in
direct contact to the tumor cells.
4. Discussion
The failure of eﬀective therapy regimens in malignant GBM
is highly associated with its malignant characteristics which
means that these tumors are highly resistant to cell death
[3], possess immunosuppressive function [4] and show a
highlyinvasiveanddestructivegrowthduetotheirmigratory
and invasive growth potential [5]. A therapeutic substance
withmultimodalfunctionabletodecreaseGBMcellmotility,
to induce antitumoral immunity and to inhibit GBM cell
proliferation might be of high value in tumor treatment. In
this study, we showed for the ﬁrst time that the mistletoe
extract ISCADOR, and especially the lectin rich variantEvidence-Based Complementary and Alternative Medicine 11
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Figure 7: ISCADOR Q reduces the growth of subcutaneously growing GBM in mice. (a) and (b) The cells were pretreated with ISCADOR
Q (100μg/mL) or were left untreated. One million viable LNT-229 cells were implanted into the right ﬂank of nude mice (a), or one
million SMA560 cells into VMDk-mice (b) Tumor size was measured 3 times per week. Inlet: As a control and to avoid the measurement of
artifacts induced by ISCADOR Q mediated inhibition of cell growth, proliferation of implanted cells was assessed by crystal violet staining
in parallel. (c) One million LNT-229 cells were implanted into the right ﬂank of nude mice and tumors were allowed to grow for six days.
At day 7 subcutaneous injections twice a week with PBS or a weekly increasing dose of ISCADOR Q (1 up to 100μg in total, arrows indicate
ISCADORinjections)weregivenonthecontralateralbodysite.Aftertwoweeksoftreatmentwiththehighestdosage,injectionswerestopped
and tumor size was measured as in (a). (d) One million SMA560 cells were implanted into the right ﬂank of VMDk mice and tumors were
allowed to grow for six day. On day 7, a single intratumoral injection of ISCADOR Q (20μL, 100μg/mL, indicated by an arrow) was given
into the palpable tumors. Tumor size was measured as in (a).
ISCADOR Q, not only reduced GBM cell growth and
induced NK cell mediated GBM cell lysis, but also impaired
the migration and invasion of GBM cells in vitro and delayed
tumor growth in vivo. These eﬀects seemed, at least in part,
to be caused by an ISCADOR induced downregulation of
glioma-associated genes involved in proliferation, survival
andtumorcellmotility(Figure 1(a)).Inaddition,ISCADOR
treatment further led to a signiﬁcant reexpression of genes
which are usually downregulated in glioblastomas and a
down-regulation of genes associated with malignant pro-
gression of gliomas (Figure 1(f)). These ﬁndings point to
a therapeutic eﬀect of ISCADOR on gene clusters associated
with gliomagenesis and glioma progression thereby exert-
ing antitumor functions. The expression of several genes
regulating proliferation (EGFR, PKB, STAT3) as well as
survival (BIRC5/survivin) and especially the secretion of
several factors relevant for cell motility was also mitigated by
ISCADOR Q, the most important being TGF-β and MMP-
2, knowing that TGF-β regulates MMP-2 [37]. Reduced
secretion did not result from a general inhibition of protein
secretion as there was no diﬀerence in the overall amount
of secreted proteins (data not shown), and there were also12 Evidence-Based Complementary and Alternative Medicine
several other proteins we examined that did not show any
diﬀerence in expression or secretion after ISCADOR Q
treatment (Figures 4,a n d6). Reduced secretion of MMP-
2, being one of the most important proteins for ECM
destruction and a well-known inducer of GBM cell motility
[52, 53], was accompanied by the reduction of the activity of
either pro- and mature MMP-2 variants as well as of MMP-9
(Figures 6(c) and 6(d)). Even if there was reduced expression
of MMP-9 mRNA upon ISCADOR treatment (Figure 4(a)),
there was an enhancement in extracellular pro-MMP-9
(Figures 6(a) and 6(b)) suggesting that ISCADOR might
alsoalterbiologicalprocessesdiﬀerentiallyregulatingprotein
secretion. But to unravel the mechanism of this observation
needs further investigation. In this context, ISCADOR Q
mediated downregulation of TIMP-2 (Figures 6(a) and
6(b)) should also be kept in mind. TIMP-2 was originally
characterized as an inhibitor of MMP, and in this light, the
downregulation of TIMP-2 and accompanied simultaneous
reduction of MMP-2 activity seemed prima facie not ﬁt. But
meanwhile it has been shown that TIMP-2 can also act as
an activator for MMP-2, thereby increased levels of TIMP-
2 can lead to increased MMP-2 activity, too [50, 51]. For
this reason ISCADOR Q mediated reduction of TIMP-2 ﬁts
well to decreased MMP-2 activity and impaired cell motility
in ISCADOR Q treated GBM cells. The secretion of two
additional factors related to tumor growth and motility as
well as to angiogenesis, was also decreased in ISCADOR Q
treated GBM cell: VEGF, whose expression is known in GBM
to be correlated with MMP-2 [54] and Angiopoietin-1, a
factor suggested to regulate, beside angiogenesis, GBM cell
adhesion to the ECM via its receptor Tie-2 [55]. Reduced
expression of VEGF and Ang-1 might therefore not only
be suggested to contribute to the antimigratory/anti-invasive
eﬀect of ISCADOR, but also to contribute to reduced tumor
neoangiogenesis.
In the literature ISCADOR has been described as an
immune stimulating agent [6–10, 13, 34, 56, 57]. In the
present study, ISCADOR treatment of GBM cells led to an
increased NK cell mediated, but not T cell mediated tumor
cell lysis (Figure 3). The mechanism by which ISCADOR
enhanced NK cell dependent GBM cell lysis is still not com-
pletely unraveled, but it was clearly not an eﬀect of directly
striking NK cells nor of altered immune receptor/ligand
surface expression on either GBM or immune cells. Neither
regulation of NKG2DL, DNAM-1-ligand, or MHC class
molecules on GBM cells, nor alterations of the appropriate
receptors on NK cells, were detectable upon ISCADOR
treatment. The immune stimulating eﬀect of ISCADOR
might be, on the one hand, an eﬀect of reduced secretion of
theprominentimmunosuppressivecytokineTGF-β[4,5,58]
in ISCADOR treated GBM cells, on the other hand might
result from the strengthened attachment of NK cells to the
surface of ISCADOR treated GBM cells, by this mechanism
forcing the contact between immune eﬀector and tumor
target cells. Since the boosted attachment was restricted to
the lectin rich ISCADOR variant Q, this eﬀect is suggested
to be a result of high ML concentration on the target tumor
cell surface (Figure 4(d)). The immune stimulating eﬀect of
ISCADOR Q was best if tumor cells are directly exposed
to the agent, since we have shown that in vitro treatment
of NK cells with ISCADOR provided no immune stimula-
tion. In vivo using two diﬀerent mouse models (syngeneic
and xenograft) and two diﬀerent therapeutic approaches
(systemic or intratumoral ISCADOR Q application) we
demonstrated that ISCADOR Q delayed tumor growth. Sub-
cutaneousinjection,ofISCADORQinmiceharboringGBM
tumors at the contralateral body ﬂank showed only marginal
and not signiﬁcant tumor growth reduction. In contrast,
local intratumoral treatment of tumors with ISCADOR Q
signiﬁcantly reduced tumor growth again suggesting that
ISCADOR unfurls its antitumoral eﬀect best when in direct
contact to the target cells (Figures 7(c) and 7(d)).
5. Conclusions
In conclusion, we here present that ISCADOR treatment
reduces the expression of genes associated with tumor
progression, decreased GBM cell growth, mitigated GBM
cell migration and invasion, and enhanced NK cell mediated
GBM cells lysis. These transcriptional changes translated
into a functionally relevant reduction of cell proliferation,
a decrease of the migratory and invasory capacity as well
as a decline in the immune evasory potential of glioma
cells.I nv i v o ,ISCADOR Q reduced tumor growth in both
xenograft and syngeneic GBM mouse model. To display
its best antitumoral function, ISCADOR Q and especially
ML have to be in a close contact to the tumor cells. Thus,
ISCADORQmayholdpromiseasamultimodalantitumoral
agent for concomitant treatment of human GBM.
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